Key points are not available for this paper at this time.
Most paediatric inflammatory bowel disease IBD studies are performed after medications are approved in adults, and the majority of participants in these studies are adolescents. We hypothesised that adolescent-onset IBD is not fundamentally different from adult-onset IBD. If this is correct, the value of delaying access to novel drugs in adolescents becomes questioned.
Rosh et al. (Fri,) studied this question.